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Abstract
Purpose: Stereotactic radiosurgery (SRS) in combination with immunotherapy (IMT) or targeted
therapy is increasingly being used in the setting of melanoma brain metastases (MBMs). The syn-
ergistic properties of combination therapy are not well understood. We compared the distant intracranial
failure rates of intact MBMs treated with SRS, SRS + IMT, and SRS + targeted therapy.
Methods and materials: Combination therapy was defined as delivery of SRS within 3 months
of IMT (anti-CTLA-4 /anti-PD-1 therapy) or targeted therapy (BRAF/MEK inhibitors). The primary
endpoint was distant intracranial failure after SRS, which was defined as any new MBM identi-
fied on brain magnetic resonance imaging. Outcomes were evaluated using the Kaplan Meier method
and Cox proportional hazards.
Results: A total of 72 patients with melanoma with 233 MBMs were treated between April 2006
and April 2016. The number of MBMs within each treatment group was as follows: SRS: 121;
SRS + IMT: 48; and SRS + targeted therapy: 64. The median follow-up was 8.9 months. One-
year distant intracranial control rates for SRS, SRS + IMT, and SRS + targeted therapy were 11.5%,
60%, and 10%, respectively (P < .001). On multivariate analysis, after adjusting for steroid use and
number of MBMs, SRS + IMT remained associated with a significant reduction in distant intra-
cranial failure compared with SRS (hazard ratio [HR], 0.48; 95% confidence interval [CI], 0.29-
0.80; P = .003) and compared with SRS + targeted therapy (HR, 0.41; 95% CI, 0.25-0.68; P = .001).
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One-year local control for SRS, SRS + IMT, and SRS + targeted therapy was 66%, 85%, and 72%,
respectively (P = .044). On multivariate analysis, after adjusting for dose, SRS + IMT remained as-
sociated with a significant reduction in local failure compared with SRS alone (HR, 0.37; 95% CI,
0.14-0.95; P = .04).
Conclusions: SRS with immunotherapy is associated with decreased distant and local intracra-
nial failure compared with SRS alone. Prospective studies are warranted to validate this result.
© 2017 The Author(s). Published by Elsevier Inc. on behalf of the American Society for
Radiation Oncology. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
The incidence of cutaneous melanoma has steadily in-
creased over the last 2 decades, with an estimated 87,110
adults to be diagnosed in 2017.1,2 Approximately 50% of
patients with melanoma either present with brain metas-
tases or develop brain metastases during the course of their
treatment.3 More than 90% of patients with melanoma brain
metastases (MBMs) will die from progression of their in-
tracranial disease.4 Compared with patients with brain
metastases from breast or lung cancer, patients with MBMs
have an almost 3-fold increased risk of neurologic death.5
Novel therapeutic agents such as immunotherapy (IMT)
consisting of anti-CTLA-4 and/or anti-PD-1 therapy and
targeted agents, consisting of BRAF and MEK inhibitors,
have been shown to improve overall survival (OS) in pa-
tients with advanced melanoma, shifting the treatment
paradigm away from conventional chemotherapy.6-9 Single-
arm, prospective studies examining the role of these agents
in the setting of MBM have shown intracranial response
rates varying from 5% to 39%.10,11 Retrospective studies of
the combined efficacy of SRS with either IMT or BRAF/
MEK inhibitors have shown acceptable safety profiles10-12
and have suggested that the timing of IMT with respect to
SRS may differentially affect outcome.11,13 However, only
1 study compared IMT and targeted therapy against one
another in the setting of SRS for MBMs and did not find
a difference in OS or distant intracranial failure.14 Given
the paucity of data on the relative efficacy of various com-
bination regimens, we compared survival and distant
intracranial failure outcomes of SRS alone, SRS + IMT (anti-
CTLA-4 and anti-PD1 therapy), and SRS + targeted therapy
(BRAF/MEK inhibitors) from a single institution.
Methods and materials
Patient population
Patients with intact MBMs who were treated with single-
fraction SRS at Washington University in St. Louis between
April 2006 and April 2016 were identified as part of a ret-
rospective study that was approved by the institutional review
board. Patients were included if they had at least 1 follow-
up brain magnetic resonance imaging (MRI) scan. A total
of 233 MBMs in 72 patients met the inclusion criteria. Base-
line patient, tumor, and treatment data were collected in a
retrospective fashion.
Radiosurgery
All patients underwent single-fraction SRS with Leksell
Gamma Knife (Elekta Medical Systems, Stockholm,
Sweden). Patients were treated with the Perfexion model
Gamma Knife unless treated prior to April 2008, in which
case a Model C unit was utilized. A high-resolution contrast-
enhanced brain MRI and non–contrast-enhanced head
computed tomography scan were obtained for treatment
planning. A medical physicist, radiation oncologist, and neu-
rosurgeon completed target delineation and treatment
planning in concert. The prescription dose was based on
recommendations from Radiation Therapy Oncology Group
trial 90-05 with adjustments made at the discretion of the
treating physician. In general, lesions measuring ≤2 cm were
treated to 20 to 24 Gy, lesions 2.1 to 3 cm were treated to
18 Gy, and lesions >3 cm were treated to 15 Gy.
Immunotherapy and targeted therapy
Combination therapy was defined as the delivery of SRS
within 3 months of IMT (anti-CTLA–4/anti-PD-1 therapy)
or targeted therapy (BRAF/MEK inhibitors). Patients who
were not treated within 3 months of IMT or targeted therapy
either received conventional chemotherapy or interleukin-
2. IMT consisted of anti-PD-1 therapy, anti-CTLA-4 therapy,
or a combination of both. In all cases, anti-PD-1 and anti-
CTLA-4 therapy was either delivered before SRS and
continued after SRS (concurrent) or delivered after SRS.
Anti-PD-1 agents consisted of nivolumab, which was ad-
ministered at 3 mg/kg every 2 weeks, or pembrolizumab,
which was administered at 2 mg/kg every 3 weeks. Anti-
CTLA-4 therapy consisted of ipilimumab, administered over
4 infusions every 3 weeks at 3 mg/kg or 10 mg/kg. Pa-
tients who received BRAF inhibitor (vemurafenib or
dabrafenib) with or without MEK inhibitor (trametinib) har-
bored the V600E mutation. Vemurafenib was administered
at 960 mg twice daily as a single agent. The BRAF/MEK
inhibitor regimen consisted of dabrafenib 150 mg twice daily
and trametinib 2 mg daily. BRAF/MEK inhibitors were held
for 2 to 5 days prior to and after SRS.
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Patient follow-up
Patients were followed every 2 to 3 months with a brain
MRI scan. All MRI images from the time of SRS to death
or last follow-up were independently reviewed by 2 inves-
tigators (S.A. and C.A.).
Outcome measures
The primary endpoint was distant intracranial failure,
measured as the time from single-fraction SRS to the de-
velopment of a new brain metastasis or last brain MRI scan.
Distant intracranial failure was coded for each treated me-
tastasis. Therefore, if a patient underwent 2 single-fraction
SRS sessions, distant intracranial failure was coded sepa-
rately for metastases treated during the first and second
session. The treatment group for each metastasis was based
on the type of therapy received within 3 months of SRS.
OS was measured as the time from the first SRS to the time
of death or last follow-up. When analyzing OS, treatment
groups were based on the type of therapy received at first
SRS. Local failure was determined for each MBM and was
defined as an increase in the size of the treated metastasis
at any time post-SRS, unless additional imaging studies or
pathology from subsequent surgical resection noted radia-
tion necrosis or pseudoprogression. This definition of local
failure is consistent with that in our previously published
work.15
Statistical analysis
Frequency distributions between groups were assessed
with Fisher’s exact test for categorical variables and
Wilcoxon rank sum for continuous variables. Prognostic
factors were evaluated using the Kaplan Meier product-
limit method and Cox proportional hazards regression model.
Variables that were significant on Cox univariate analysis
(P < .05) were considered for Cox multivariate analysis. The
cumulative incidence of distant intracranial failure was cal-
culated using a competing risks model with death as a
competing risk factor.
Results
Patient and melanoma brain metastases
characteristics
Patient and MBM characteristics are listed in Table 1.
The treatment groups were as follows: 121 MBMs (38 pa-
tients) were treated with SRS, 48 MBMs (18 patients) were
treated with SRS + IMT, and 64 MBMs (16 patients) were
treated with SRS + targeted therapy. Within the SRS + IMT
group, 14 MBMs (29%) underwent SRS within 3 months
of both anti-PD-1 and anti-CTLA-4, 31 MBMs (65%) un-
derwent SRS within 3 months of anti-CTLA-4 alone, and
3 MBMs (6%) underwent SRS within 3 months of anti-
PD-1 alone. Patients were on anti-PD-1 and anti-CTLA-4
therapy for a median duration of 12.6 months (range, 0.23-
25.9) and 2.1 months (range, 0.8-14.2), respectively. Within
the SRS + BRAF/MEK-I group, 28 MBMs (44%) under-
went SRS within 3 months of both BRAF-I and MEF-I
therapy. Patients were on BRAF-I alone and BRAF-
I + MEK-I for a median of 7.5 months (range, 1.13-13.9)
and 11.2 months (range, 1.6-21.8), respectively. Patients who
were treated with SRS + IMT were older than those who
were treated with SRS or SRS + targeted therapy (P = .014),
had a lower number of repeat SRS sessions (P = .024), and
were more likely to be treated in a concurrent fashion
(P < .001). There were no differences between treatment
groups in terms of Karnofsky performance status, Graded
Prognostic Assessment score, dose, volume of each MBM,
and total volume of MBM per SRS. A total of 61 patients
(85%) underwent more than 1 follow-up brain MRI scan.
Steroid use prior to stereotactic radiosurgery
Steroids were initiated prior to SRS in 21 cases. The ma-
jority of these patients (n = 19) were administered
dexamethasone in doses that ranged from 2 mg daily to 4 mg
every 6 to 12 hours. One patient was taking 80 mg pred-
nisone daily for dermatomyositis and another patient was
taking 40 mg of prednisone daily for autoimmune colitis
secondary to ipilumumab use.
Distant intracranial failure and local failure
The rate of distant intracranial control at 1 year was
higher in the SRS + IMT treatment group compared with
the SRS and SRS + targeted therapy groups (60% vs 11.5%
vs 10%, P < .001; Fig 1). On multivariate analysis,
SRS + IMT remained associated with a 52% reduction in
risk of distant intracranial failure compared with SRS (hazard
ratio [HR], 0.48; 95% confidence interval [CI], 0.29-
0.80; P = .003) and a 59% reduction in risk of distant
intracranial failure compared with SRS + targeted therapy
(HR, 0.41; 95% CI, 0.25-0.68, P = .001; Table 2). When
using death as a competing risk, the cumulative incidence
of distant intracranial failures was also significantly reduced
in the SRS + IMT treatment group compared with treat-
ment without IMT (subhazard ratio, 0.51; 95% CI, 0.33-
0.78; P = .002). As a robustness check, the analysis was
repeated after excluding patients who received whole brain
radiation prior to the first SRS (n = 7), and results re-
mained unchanged (Suppl Fig S1).
On subgroup analysis, SRS within 3 months of both anti-
PD-1 and anti-CTLA-4 (n = 14) resulted in improved
6-month distant intracranial control compared with
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anti-PD-1 or anti-CTLA-4 alone (n = 34; 84% vs 50%;
P = .016). When stratifying the SRS + targeted therapy group
on the basis of BRAF + MEK-I (n = 28) versus BRAF–I
alone (n = 36), SRS within 3 months of BRAF + MEK-I
resulted in improved 6-month distant intracranial control
compared with BRAF-I alone (45% vs 21%; P = .011).
The local control rate also differed significantly between
treatment groups (SRS vs SRS + IMT vs SRS + targeted
therapy: 66% vs 85% vs 72%; P = .044; Fig 2). On uni-
variate analysis, treatment group, number of MBMs, and
dose were significantly associated with local control
(Table 3). Dose, both as a continuous variable and dichoto-
mized at 20 Gy, was significant on univariate analysis;
however, dose >20 Gy was carried into the multivariate
analysis due to its larger effect size. On multivariate
analysis, SRS + IMT (compared with SRS alone) and
dose >20 Gy remained significantly associated with a
decreased risk of local failure (HRSRS+IMT, 0.37; 95% CI,
0.14-0.95; P = .04; HRdose>20 Gy, 0.22; 95 CI, 0.08-0.61,
P = .004).
Survival analysis
The median follow-up was 8.9 months for all patients
and 12 months for patients who were alive at the time of
analysis. For patients who were not alive at the time of the
analysis, the median time between last brain MRI and death
was 1.7 months. One-year OS was higher in patients who
were initially treated with SRS + IMT during the first SRS
session compared with patients who were treated without
IMT (58% vs 31%, P = .016; Fig 3). However, on multi-
variate analysis, only total volume of intracranial disease
at first SRS and steroid use prior to first SRS remained sig-
nificantly associated with OS (Suppl Table S1).
Table 1 Patient and MBM characteristics
Patient/Tumor Characteristics SRS SRS + IMT SRS + BRAF/MEK P-valuea
No. of Patients 38 18 16
No. of MBMs 121 48 64
Median age (range), y 56 (31-81) 61 (36-86) 52 (31-65) .014
KPS at first SRS, n (%) .628
60 1 (3) 0 0
70 4 (11) 0 0
80 13 (34) 4 (22) 5 (31)
90 16 (42) 9 (50) 4 (25)
100 4 (11) 5 (28) 7 (44)
GPA at first SRS, n (%) .876
1 5 (13) 1 (6) 1 (6)
2 10 (26) 5 (28) 8 (50)
3 13 (34) 7 (39) 6 (38)
4 10 (26) 5 (0) 1 (6)
Male: Female 31:7 12:6 6:10 1.0
Whole-brain radiation therapy prior to first SRS 3 1 3 1.0
Median dose (range), Gy 20 (11.2-24) 20 (15-24) 18 (16-24) .119
Median volume (mm3) per MBM (range) 362 (14-23,700) 329 (4-13,520) 112 (3-22,410) .234
Median total volume (mm3) per SRS (range) 2096 (88-36,695) 1415 (50-26,417) 931 (12-32,825) .055
Median no. of MBMs per SRS (range) 3 (1-11) 4 (1-6) 4 (1-6) .228
Median no. of SRS sessions per patient (range) 1 (1-3) 1 (1-2) 1 (1-4) .024
Timing of IMT/BRAF/MEK-I, n (%) < .001
Prior to SRS N/A 0 (0) 9 (14)
After SRS N/A 3 (6) 13 (20)
Concurrent SRS N/A 45 (94) 42 (66)
Steroid use prior to SRS .416
Yes 22 (18) 7 (15) 17 (15)
No 99 (81) 41 (85) 47 (73)
Systemic disease prior to SRS, n (%) .188
NED 3 (2) 7 (14) 15 (23)
PD 68 (56) 27 (56) 21 (33)
PR 5 (4) 1 (2) 14 (22)
SD 45 (37) 13 (27) 14 (22)
GPA, graded prognostic assessment; IMT, immunotherapy; KPS, Karnofsky performance status; MBM, melanoma brain metastasis; N/A, not avail-
able; NED, no evidence of disease; PD, progressive disease; PR, partial response; SD, stable disease; SRS, stereotactic radiosurgery.
a Comparison of IMT + SRS therapy to all other treatment groups.
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Toxicity
Two patients developed seizures the day after SRS and
required hospitalization. One of these patients was treated
with SRS alone and the other was treated with SRS + BRAF-
I. Pathology findings from emergent surgical resection in
both cases confirmed metastatic melanoma with large areas
of hemorrhage. Another patient developed headaches 5
months after SRS + BRAF-I, which persisted despite dexa-
methasone. MRI revealed hemorrhage in 2 MBMs, which
required surgical resection. Pathology confirmed meta-
static melanoma in 1 lesion and predominant radiation
necrosis in another. One patient who was treated with
SRS + IMT underwent laser ablation of an MBM for pre-
sumed radiation necrosis. Biopsies were not obtained for
pathologic review.
Discussion
Our results yield 3 important findings. First, the com-
bined treatment of SRS + IMT is associated with decreased
distant intracranial failures compared with both SRS and
SRS + targeted therapy. Even after adjusting for the number
of MBMs, volume of intracranial disease, and steroid use
prior to SRS, treatment with SRS + IMT was associated with
a significant decrease in distant intracranial failure. Ahmed
et al compared the outcomes of SRS + targeted therapy with
those of SRS + IMT and SRS alone.14 They also found that
SRS + IMT was associated with improved distant intra-
cranial control when compared with SRS alone but not when
compared with SRS + targeted therapy. Their 1-year distant
intracranial control rates of 5% versus 8% versus 20% for
MBMs treated with SRS versus SRS + BRAF-I versus
SRS + BRAF/MEK-I, respectively, are not very different
from our rate of 11% for both SRS and SRS + targeted
therapy.14 However, our 1-year distant intracranial failure
for SRS + IMT is higher than that reported by Ahmed et al.
One explanation for this may be that the majority of pa-
tients in our study were treated with concurrent IMT, and
all patients were continued on IMT after SRS. Kiess et al
reported improved distant intracranial control rates for pa-
tients who received IMT after, rather than before, SRS.11
When interpreting our results, it is important to ac-
knowledge the heterogeneity in the SRS + IMT treatment
group. Twenty-nine percent of MBMs within this group un-
derwent SRS within 3 months of both anti-PD-1 and anti-
CTLA-4. The remaining MBMs were treated within 3
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Figure 1 Distant intracranial control of 233 melanoma brain me-
tastases across 215 stereotactic radiosurgery sessions stratified by
receipt of immunotherapy (anti-CTLA-4/anti-PD-1) or targeted
therapy (BRAF/MEK-inhibitors).
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Figure 2 Local control of 233 melanoma brain metastases strati-
fied by receipt of immunotherapy (anti-CTLA-4/anti-PD-1) or
targeted therapy (BRAF/MEK-inhibitors).



























Figure 3 Overall survival in patients with melanoma brain me-
tastases who were treated with or without immunotherapy during
the first stereotactic radiosurgery.
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months of single-agent anti-PD-1 (6%) or anti-CTLA-4
(65%). Although our study numbers are small, on sub-
group analysis, distant intracranial control was higher when
both anti-PD-1 and anti-CTLA-4 were delivered within 3
months of SRS compared with either agent alone. This is
consistent with data from Checkmate 067, which showed
improved progression-free survival in patients who re-
ceived both anti-PD-1 and anti-CTLA-4 compared with anti-
CTLA-4 alone. However, it should be noted that patients
with brain metastases were excluded from this study. Studies
with large numbers of MBMs are needed to determine
whether the benefit of improved distant intracranial control
is limited to patients who receive both anti-PD-1 and
anti-CTLA-4 therapy in a concurrent or sequential
fashion.
There is also some degree of heterogeneity within the
SRS + targeted therapy group. Forty-four percent of MBMs
within this group underwent SRS within 3 months of BRAF-
I + MEK-I, and the remaining MBMs underwent SRS within
3 months of BRAF-I alone. On subgroup analysis, SRS
within 3 months of both BRAF + MRK-I was associated
with improved distant intracranial control compared with
BRAF-I alone. This is consistent with several random-
ized control trials that showed improved progression-free
survival in patients with advanced melanoma who under-
went combination BRAF-I + MEK-I compared with BRAF-I
alone.8,16
Second, similar to distant intracranial control, local
control was superior in MBMs that were treated with
SRS + IMT compared with SRS alone, after adjusting for
Table 2 Univariate and multivariate analysis for distant intracranial failure
Univariate Analysis Multivariate Analysis
Variable HR (95% CI) P-value HR (95% CI) P-value
Treatment Group
SRS 1 .176 1 .317
SRS + BRAF/MEK-I 1.25 (0.90-1.74) < .001 1.18 (0.89-1.84) .003
SRS + IMT 0.42 (0.26-0.66) 0.48 (0.29-0.80)
No. of MBM per SRS 1.12 (1.05-1.18) <.001 1.09 (1.03-1.16) .005
No. of SRS sessions 0.83 (0.61-1.14) .246 –
Volume (mm3)a 1.16 (1.04-1.28) .005 1.02 (0.90-1.16) NS
Dose (cGy) 0.99 (0.98-0.99) .019 1.00 (0.99-1.00) NS
Sex
Male 1 .693 –
Female 1.07 (0.76-1.50)
KPS at time of SRS
60 1 .232 –
70 0.33 (0.05-2.01) .305 –
80 0.48 (0.11-1.97) .176 –
90 0.38 (0.09-1.55) .185 –
100 0.38 (0.09-1.59)
GPA at time of SRS
1 1 .928 1.23 (0.70-2.16) NS
2 1.01 (0.68-1.52) .167 1.23 (0.68-2.24) NS
3 0.74 (0.48-1.14) .032 1.25 (0.54-2.88) NS
4 0.49 (0.26-0.94)
Age 0.99 (0.98-1.0) .064 –
Prior WBI
No 1 .434 –
Yes 1.18 (0.78-1.80)
Steroid use prior to SRS
No 1 < .001 1 .002
Yes 2.07 (1.42-2.99) 1.81 (1.25-2.64)
Systemic disease
NED 1 .507 –
PD 0.85 (0.54-1.36) .313 –
PR 0.73 (0.39-1.35) .522
SD 0.85 (0.52-1.39)
CI, confidence interaval; GPA, graded prognostic assessment; IMT, immunotherapy; HR, hazard ratio; KPS, Karnofsky performance status; MBM,
melanoma brain metastasis; NED, no evidence of disease; NS, not shown; PD, progressive disease; PR, partial response; SD, stable disease; SRS,
stereotactic radiosurgery; WBI, whole-breast irradiation.
a Volume (mm3) is log transformed and represents total volume of intracranial disease at a given SRS treatment.
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dose. Qian et al showed that SRS within 4 weeks of IMT
resulted in a greater reduction of MBM volume at 1.5 and
6 months compared with SRS delivered more than 4 weeks
from IMT.13 A greater response rate was also observed in
patients who were treated with anti-PD-1 therapy com-
pared with patients who were treated with anti-CTLA-4
therapy. We did not have a sufficient number of patients
who were treated within 4 weeks of SRS to study the
relationship between timing of IMT and local or distant
control.
Third, combination therapy, as delivered in our patient
population, appears to be well tolerated with no unanticipated
neurotoxic events. There were only 2 cases of radiation ne-
crosis and 2 cases of seizures secondary to hemorrhagic
MBMs that required emergent surgery. Given that MBMs
have a 10% probability of hemorrhage after SRS, this would
not be considered unusual.17 Others have reported accept-
able toxicity profiles when combining SRS with BRAF-I
or IMT.18-20 Due to the low number of events, a formal analy-
sis of predictors for neurotoxicity was not possible.
Table 3 Univariate and multivariate analysis for local failure
Univariate Analysis Multivariate Analysis
Variable HR (95% CI) P-value HR (95% CI) P-value
Treatment Group
SRS 1 .176 0.51 (0.26-1.01) .054
SRS + BRAF/MEK-I 0.63 (0.32-1.23) .028 0.37 (0.14-0.95) .040
SRS + IMT 0.34 (0.13-0.89)
No. of MBM per SRS 1.15 (1.04-1.28) .007 1.07 (0.96-1.20) NS




Total Volume (mm3)a 1.08 (0.89-1.31) .422 –
Dose (Gy) 0.75 (0.66-0.85) < .001 –
Dose >20 Gy
No 1 .005 1 .004
Yes 0.23 (0.08-0.64) 0.22 (0.08-0.61)
Gender
Male 1 .436 –
Female 1.27 (0.69-2.35)
KPS at time of SRS
100 1 .120 –
90 1.95 (0.84-4.53) .125 –
80 2.02 (0.82-4.96) .725 –
70 1.45 (0.18-11.88) –
60 No events
GPA at time of SRS
1 1 .532 –
2 1.33 (0.54-3.26) .556 –
3 0.73 (0.27-2.03) .353 –
4 1.68 (0.56-5.0)
Age 1.01 (0.99-1.02) .530 –
Prior WBI
No 1 .697 –
Yes 0.81 (0.29-2.28)
Steroid prior to SRS
No 1 .843 –
Yes 1.09 (0.46-2.58)
Systemic disease
SD 1 .775 –
PR 0.85 (0.27-2.63) .129 –
PD 1.68 (0.85-3.27)
NED No events
CI, confidence interaval; GPA, graded prognostic assessment; IMT, immunotherapy; HR, hazard ratio; KPS, Karnofsky performance status; MBM,
melanoma brain metastasis; NED, no evidence of disease; NS, not shown; PD, progressive disease; PR, partial response; SD, stable disease; SRS,
stereotactic radiosurgery; WBI, whole-breast irradiation.
a Volume (mm3) is log transformed and represents total volume of intracranial disease at a given SRS treatment.
Advances in Radiation Oncology: October-December 2017578 S. Acharya et al.
Although 1-year OS was greater in patients who were
initially treated with SRS + IMT compared with those who
were treated without IMT, this benefit did not hold on mul-
tivariate analysis when accounting for total volume of
intracranial disease and steroid use. A review of the literature
demonstrates mixed results, with some retrospective studies
demonstrating a favorable association between SRS + IMT
and OS and others finding no association.14,20,21 Inconsis-
tences may be due to the fact that not all retrospective studies
control for variables such as tumor volume or steroid use
in their multivariate model.
Evasion of the immune system is a known hallmark of
metastatic disease, and there is an emerging hypothesis that
coadministration of radiation and IMT may enhance the
immune system’s response to cancer.22 This hypothesis stems
from the observation that radiation, particularly in high doses,
upregulates inflammatory cytokines that promote tumor
lymphocyte infiltration and presentation of neoantigens in
the tumor microenvironment, thereby increasing the
immunogenicity of tumors.23,24 This effect, coupled with
anti-CTLA-4 and anti-PD-1 therapy, may result in a height-
ened immune response to cancer cells.25,26
Our results add credence to this hypothesis because
MBMs that were treated with SRS and anti-CTLA-4/anti-
PD-1 therapy had improved distant intracranial control
compared with patients who did not receive IMT. However,
given the retrospective nature of this study, robust pro-
spective studies are needed to formally test the presence
of a synergistic effect between SRS and IMT. Such
prospective studies are already underway with 4 actively
enrolling trials combining IMT and SRS for MBMs
(ClinicalTrials.gov identifiers: NCT01703507, NCT1950195,
NCT01689974, NCT02107755). However, questions still
remain regarding the sequence and time interval between
the 2 therapies, whether steroids can be administered without
decreasing efficacy of IMT, and how and when to measure
response to therapy.
The limitations of this study include its retrospective
nature, small patient numbers, and heterogeneity within treat-
ment groups. Our results should be interpreted with the
understanding that 29% of MBMs within the SRS + IMT
group were treated with both anti-PD-1 and anti-CTLA-
4, and 44% of MBMs within the SRS + targeted therapy
group were treated with both BRAF-I and MEK-I. Al-
though patients do cross over from 1 drug class to another
and such crossovers could potentially confound our results,
there was no difference in the proportion of patients who
remained on IMT or targeted therapy until the date of last
follow-up or distant intracranial failure. Therefore, differ-
ences in the crossover rates between treatment groups are
unlikely to explain the difference in outcomes.
Additional limitations to this study include the fact that
the primary endpoint and the time interval between sys-
temic therapy and SRS were not prespecified. A 3-month
time interval was chosen on the basis of our patient popu-
lation and its use in prior studies.14 Selection biases may
also influence the results of our study because patients who
require steroids for symptom management may be less likely
to be treated with IMT. To reduce the influence of such
biases, we controlled for steroid use in our multivariate
analysis. Toxicity may also be underreported because tox-
icity data were collected in a retrospective fashion.
Conclusion
Despite the study limitations, our data represent one of
the few published series comparing outcomes of SRS versus
SRS + targeted therapy versus SRS + IMT in intact MBMs
and provides insight into combination therapy that war-
rants prospective validation. Because the majority of patients
with MBMs die from progression of intracranial disease,
there may be opportunities to improve outcomes through
optimal combinations of SRS and IMT.
Supplementary data
Supplementary material related to this article can be
found at https://doi.org/10.1016/j.adro.2017.07.003.
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